A systematic review of biomarkers for immunotherapy in microsatellite-stable colorectal cancer identified POLE/POLD1 mutations as genomic "hard" indicators recommended by NCCN guidelines, while objective response rates to immune checkpoint inhibitors remain below 10% in this population. (Mol Biol Rep)
POLE/POLD1 mutations recommended as genomic indicators for immunotherapy in MSS colorectal cancer
The CRC Digest